Author

B. L. Ebert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Biochemistry· 1 Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

E. S. Fischer· 3 shared A. Choudhary· 2 shared B. J. Groendyke· 2 shared B. Sandoval· 2 shared C. Y. Jin· 2 shared D. R. Liu· 2 shared J. Qi· 2 shared K. A. Donovan· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

E. S. Fischer

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Exploration of the Tunability of BRD4 Degradation by DCAF16 Trans-labelling Covalent Glues

M. M. Hassan, Y.-D. Li, M. W. Ma, M. Teng, W. S. Byun, K. Puvar, R. Lumpkin, B. Sandoval, J. C. Rutter, C. Y. Jin, M. Y. Wang, S. Xu, A. M. Schmoker, H. Cheong, B. J. Groendyke, , N. Gray

This study evaluates how electrophilic modifications to JQ1 affect DCAF16 trans-labeling and BRD4 degradation, showing a correlation between warhead exposure and degradation efficiency.

bioRxiv · Oct 7, 2023 · PreprintPharmacology & Toxicology

A molecular glue approach to control the half-life of CRISPR-based technologies

V. Sreekanth, M. Jan, K. T. Zhao, D. Lim, J. R. Davis, M. McConkey, V. Kovalcik, S. Barkal, B. K. Law, J. Fife, R. Tian, M. E. Vinyard, B. Becerra, M. E. Kampmann, R. I. Sherwood, , A. Choudhary

This paper introduces a molecular glue approach using pomalidomide to control the half-life of CRISPR-based technologies, enabling precise regulation of their activity and therapeutic potential.

bioRxiv · Mar 12, 2023Bioengineering

Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders

Y.-D. Li, M. W. Ma, M. M. Hassan, M. Hunkeler, M. Teng, K. Puvar, R. Lumpkin, B. Sandoval, C. Y. Jin, S. B. Ficarro, M. Y. Wang, S. Xu, B. J. Groendyke, L. H. Sigua, I. Tavares, , B. L. Ebert

This paper describes a new mechanism for molecular glue degraders called template-assisted covalent modification, showing how BRD4 degraders recruit CUL4DCAF16 to degrade BRD4.

bioRxiv · Feb 14, 2023Biochemistry

Proteolysis Targeting Chimeras With Reduced Off-targets

T. M. Nguyen, V. Sreekanth, A. Deb, P. Kokkonda, P. K. Tiwari, K. A. Donovan, V. M. Shoba, S. K. Chaudhary, J. A. M. Mercer, S. Lai, A. Sadagopan, M. Jan, E. S. Fischer, D. R. Liu, B. L. Ebert, A. Choudhary

This study develops a platform to identify off-target degradation of ZF proteins by PROTACs and identifies design rules to reduce off-target effects using pomalidomide analogs.

bioRxiv · Nov 18, 2021Pharmacology & Toxicology

CBL mutations promote activation of PI3K/AKT signaling via LYN kinase

R. Belizaire, S. H. J. Koochaki, N. Udeshi, A. Vedder, L. Sun, T. Svinkina, C. Hartigan, C. Stanclift, M. Schenone, S. A. Carr, E. Padron, B. L. Ebert

The paper investigates how CBL mutations drive oncogenesis by enhancing LYN kinase activity and PI3K/AKT signaling, suggesting LYN inhibition as a therapeutic strategy.

bioRxiv · Apr 13, 2020 · PreprintCancer Biology